1234708-04-3

• 常用中文名：HPGDS-IN-1
• 常用英文名：hPGDS-IN-1
• CAS号：1234708-04-3
• 分子式：C₂₂H₂₀N₆O₃
• 分子量：416.43300
• 相关类别： 信号通路 免疫及炎症 PGE合成酶
• 发布时间：2018-03-31 06:19:54
• 更新时间：2026-07-16 17:52:16
• hPGDS-IN-1是一种hPGDS抑制剂, 荧光偏振检测或EIA法测得IC50值为12 nM。

名称

• 中文名: HPGDS-IN-1
• 英文名: 2-(pyridin-2-yl)pyrimidine-5-carboxylic acid 3-[5-(1-hydroxy-1-methylethyl)-1,2,4]oxadiazol-3-yl-benzylamide
• 中文别名: N-[[3-[5-(1-羟基-1-甲基乙基)-1,2,4-恶二唑-3-基]苯基]甲基]-2-(2-吡啶基)-5-嘧啶甲酰胺; N-(3-(5-(2-羟基丙-2-基)-1,2,4-恶二唑-3-基)苄基)-2-(吡啶-2-基)嘧啶-5-甲酰胺
• 英文别名: Inhibitor,inhibit,hPGDS IN 1,Prostaglandin E synthase,hPGDSIN1,PGE synthase; S191801,2-Pyridin-2-yl-pyrimidine-5-cboxylic acid 3-[5-(1-hydroxy-1-methyl-ethyl)-[1,2,4]oxadiazol-3-yl]-benzylamide; 5-Pyrimidinecboxamide, N-[[3-[5-(1-hydroxy-1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-2-(2-pyridinyl); hPGDS-IN-1, 10 mM in DMSO; N-[[3-[5-(1-Hydroxy-1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-2-(2-pyridinyl)-5-pyrimidinecboxamide; 2-(pyridin-2-yl)pyriMidine-5-cboxylic acid 3-[5-(1-hydroxy-1-Methylethyl)-1,2,4]oxadiazol-3-yl-benzylaMide; hPGDS-IN-1 (S191801); tert-butyl(((3,4R,6-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)diphenylsilane S191801; N-({3-[5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-2-(pyridin-2-yl)pyrimidine-5-cboxamide; EOS-61636; 2-pyridin-2-yl-pyrimidine-5-carboxylic acid 3-[5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl]benzylamide; SAR-191801; S191801; N-(3-(5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)-2-(pyridin-2-yl)pyriMidine-5-cboxaMide

物化性质

• 分子式: C₂₂H₂₀N₆O₃
• 分子量: 416.43300
• 精确质量: 416.16000
• PSA: 126.92000
• LogP: 3.13690
• 储存条件: 2-8℃

生物活性

• 描述: hPGDS-IN-1是一种hPGDS抑制剂, 荧光偏振检测或EIA法测得IC50值为12 nM。
• 相关类别:
  信号通路 >> 免疫及炎症 >> PGE合成酶
  研究领域 >> 炎症/免疫
• 参考文献:

  [1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.

  [2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.

  [3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 19